Is Pueraria Menopause Randomized Trial safe?

The current Migaku evidence database contains 2 reusable source documents for Pueraria Menopause Randomized Trial. This answer focuses on safety, limits, and clinician-discussion contexts. - It has long been utilized in ethnomedicine for estrogen-related conditions and age-associated functional decline. [Zeng H (2026); evidence level 3] - This review critically evaluates the nexus between its botanical characteristics, traditional ethnopharmacological uses, and contemporary evidence regarding its therapeutic potential. [Zeng H (2026); evidence level 3] - Materials and methods A structured literature search was conducted across multiple international and Chinese databases up to 2025, with screening based on predefined inclusion and exclusion criteria focusing on botanical identity, chemical composition, pharmacological activity, toxicological evidence, and clinical findings. [Zeng H (2026); evidence level 3] - mirifica (Airy Shaw and Suvat.) Niyomdham ( Pueraria mirifica ), locally known as "White Kwao Krua" or "white kudzu", is a renowned medicinal botanical drug indigenous to Southeast Asia, particularly Thailand and Myanmar. [Zeng H (2026); evidence level 3] - The herbal gel group demonstrated a more significant reduction in atrophic vaginitis indicators compared to placebo (P Conclusion Both interventions effectively reduced symptoms and improved quality of life, but the herbal gel outperformed auriculotherapy in reducing dryness and enhancing sexual function. [Naderi-Afshar E (2026); evidence level 4] Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording. This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.